Selection of P2Y12 antagonist in patients with myocardial infarction who received thrombolytic therapy. Results of annual follow-up of TREAT study patients
https://doi.org/10.15829/1560-4071-2019-9-64-70
Abstract
Dual antiplatelet therapy serves to improve the clinical results of thrombolytic therapy after STEMI, until recently consisted of acetylsalicylic acid and clopidogrel. In this category of patients, ticagrelor, widely used by acute coronary syndrome as more effective than clopidogrel, had no serious evidence of efficacy and safety. The TREAT study discussed in this article has been implemented to supply a gap in the evidence base of ticagrelor. The results of observation within 12 months after randomization to taking ticagrelor or clopidogrel of patients who received thrombolytic showed that the hemorrhagic safety regarding the major bleeding of ticagrelor is comparable with clopidogrel. The results of the TREAT study with the previously obtained results of the PLATO study make it possible to broaden indications for the use of ticagrelor (or switching from clopidogrel) in the first 24 hours from the onset of a myocardial infarction in patients who received thrombolytic therapy as an initial reperfusion.
About the Authors
O. V. Averkov
O. M. Filatov City Clinical Hospital № 15;
N. I. Pirogov Russian National Research Medical University
Russian Federation
Moscow
Russian Federation
Moscow
V. I. Vechorko
O. M. Filatov City Clinical Hospital № 15;
N. I. Pirogov Russian National Research Medical University
Russian Federation
Moscow
Russian Federation
Moscow
References
1. O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:e362-425. doi:10.1161/CIR.0b013e3182742cf6.
2. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119-77. doi:10.1093/eurheartj/ehx393.
3. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366:160721. doi:10.1016/S0140-6736(05)67660-X.
4. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352:1179-89. doi:10.1056/NEJMoa050522.
5. Wiviott ST, Braunwald E, McCabe CH, et al. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med. 2007;357(20):2001-15. doi:10.1056/NEJMoa0706482.
6. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-57. doi:10.1056/NEJMoa0904327.
7. Berwanger O, Nicolau JC, Carvalho AC, et al. Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: rationale and design of the TicagRElor in pAtients with ST elevation myocardial infarction treated with Thrombolysis (TREAT) trial. American Heart Journal 2018 Mar 3;202:89-96. doi:10.1016/j.ahj.2018.02.017.
8. Averkov OV, Vechorko VI. Ticagrelor and thrombolysis in myocardial infarction: what does the TREAT study change? Russ J Cardiol. 2018;23(9):65-70. (In Russ.) doi:10.15829/1560-4071-2018-9-65-70.
9. Berwanger O, Abdelhamid M, Alexander T, et al. Use of ticagrelor alongside fibrinolytic therapy in patients with ST-segment elevation myocardial infarction: Practical perspectives based on data from the TREAT study. Clin Cardiol. 2018;41:1322-7. doi:10.1002/clc.23043.
10. Kheiri B, Osman M, Abdalla A, et al. Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: a systematic review and meta-analysis of randomized clinical trials. J Thromb Thrombolysis. 2018;46(3):299-303. doi:10.1007/s11239-018-1706-2.
11. Velders MA, Abtan J, Angiolillo DJ, et al. Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary interventions. Heart. 2016;102:617-25. doi:10.1136/heartjnl-2015-308963.
Review
For citations:
Averkov O.V., Vechorko V.I. Selection of P2Y12 antagonist in patients with myocardial infarction who received thrombolytic therapy. Results of annual follow-up of TREAT study patients. Russian Journal of Cardiology. 2019;(9):64-70. (In Russ.) https://doi.org/10.15829/1560-4071-2019-9-64-70
Views:
826
Email this article 